NYSE$MED
Medifast Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close · Investor relations
Briefing
Medifast reported Q4 2025, revenue of $75.1M, net loss of $18.1M.
For Q4 2025, Medifast reported revenue of $75.1M, a net loss of $18.1M. Management discusses segment performance, capital allocation, and outlook in the earnings release.
- Revenue $75.1M.
- Net loss $18.1M.
- Medifast highlights liquidity, operations, and 2026 priorities.
Headline financials
Revenue & EPS history
Medifast · Revenue · Quarterly
$75.1M
Forward guidance
The release discusses Medifast's outlook for upcoming periods, including capital allocation, operating priorities, and market risks, without relying solely on numeric EPS bridges.
Tailwinds
- Medifast cites operational execution and demand trends supporting the outlook.
- Balance sheet and liquidity actions aim to fund growth and returns.
Headwinds
- GAAP profitability remained under pressure in Q4 2025.
- Macro, pricing, and input-cost volatility could pressure margins.
- Segment mix and one-time items may affect quarter-to-quarter comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2025
+0.2%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+0.4%
Avg return
30 days after
51%
33 / 65 earnings
Positive
+31.6%
Q4 2017
Best reaction
-29.9%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.2% | +19.7% | +16.7% | |
| Q4 2025 | -0.8% | -1.9% | -7.4% | |
| Q3 2025 | +0.8% | +0.4% | -8.6% | |
| Q1 2025 | -0.6% | +5.3% | +10.8% | |
| Q4 2024 | -11.4% | -8.4% | -11.1% | |
| Q3 2024 | +9.8% | +3.1% | +6.2% | |
| Q2 2024 | -5.6% | -9.0% | -11.8% | |
| Q1 2024 | -18.3% | -20.8% | -25.4% | |
| Q4 2023 | -19.2% | -18.5% | -28.7% | |
| Q3 2023 | -1.5% | -6.5% | +3.3% | |
| Q2 2023 | -9.5% | -4.9% | -18.5% | |
| Q1 2023 | -3.8% | -0.7% | -14.1% | |
| Q4 2022 | -10.8% | -4.6% | -15.3% | |
| Q3 2022 | -3.2% | -1.6% | +9.0% | |
| Q2 2022 | -15.2% | -21.9% | -31.9% | |
| Q1 2022 | +5.4% | +1.8% | -2.0% | |
| Q4 2021 | -5.6% | +1.7% | -6.4% | |
| Q3 2021 | +3.7% | +4.7% | -7.1% | |
| Q2 2021 | -8.7% | -14.1% | -17.4% | |
| Q1 2021 | +7.8% | +18.9% | +35.3% | |
| Q4 2020 | -3.9% | -0.8% | -14.7% | |
| Q3 2020 | +12.9% | +23.5% | +45.4% | |
| Q2 2020 | -5.7% | -5.0% | -8.0% | |
| Q1 2020 | +18.5% | +30.1% | +46.7% | |
| Q4 2019 | -9.7% | -13.4% | -31.5% | |
| Q3 2019 | -29.9% | -24.8% | -14.7% | |
| Q2 2019 | -7.6% | -7.8% | -10.5% | |
| Q1 2019 | -2.1% | +3.6% | -12.1% | |
| Q4 2018 | +0.9% | -0.7% | +0.3% | |
| Q3 2018 | -28.3% | -25.3% | -32.4% | |
| Q2 2018 | +25.8% | +17.4% | +35.0% | |
| Q1 2018 | +22.3% | +19.3% | +50.0% | |
| Q4 2017 | +31.6% | +32.5% | +44.0% | |
| Q3 2017 | +14.7% | +13.1% | +16.6% | |
| Q2 2017 | +18.6% | +20.7% | +31.7% | |
| Q1 2017 | +3.4% | +3.8% | -6.1% | |
| Q4 2016 | -3.7% | -4.4% | -1.4% | |
| Q3 2016 | -5.0% | -4.5% | -4.7% | |
| Q2 2016 | -0.2% | +0.8% | +5.9% | |
| Q1 2016 | +0.8% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | +6.9% | — | — | |
| Q2 2015 | -9.2% | — | — | |
| Q1 2015 | +5.3% | — | — | |
| Q4 2014 | -3.1% | — | — | |
| Q3 2014 | +2.5% | — | — | |
| Q2 2014 | -9.5% | — | — | |
| Q1 2014 | -8.5% | — | — | |
| Q4 2013 | +3.4% | — | — | |
| Q3 2013 | +0.5% | — | — | |
| Q2 2013 | -4.3% | — | — | |
| Q1 2013 | -3.8% | — | — | |
| Q4 2012 | -5.4% | — | — | |
| Q3 2012 | +10.4% | — | — | |
| Q2 2012 | +28.5% | — | — | |
| Q1 2011 | +8.9% | — | — | |
| Q1 2012 | +3.2% | — | — | |
| Q4 2011 | +0.9% | — | — | |
| Q4 2009 | +0.9% | — | — | |
| Q3 2010 | +1.9% | — | — | |
| Q3 2011 | +1.9% | — | — | |
| Q4 2010 | +4.3% | — | — | |
| Q2 2010 | +4.3% | — | — | |
| Q2 2011 | +4.3% | — | — | |
| Q1 2010 | +10.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro